November 7, 2014
The Master Class XV • 2014
Disclaimer
The recommendations provided from the authors were obtained on November 7, 2014. The opinions and recommendations do not necessarily accurately reflect the current state of affairs or the current advice the authors may choose to provide in the same circumstances. Please refer to the current guidelines or the Canadian Association of Gastroenterology (CAG) for up-to-date treatment options.
Learning Objectives
The educational objective of Mentoring in IBD XV is to increase awareness of current developments and best practices in inflammatory bowel disease (IBD) management, promote collaboration among Canadian gastroenterologists, and optimize treatment of IBD.
Participants in this program will:
- Cite core truisms that define what we know now about optimizing management in IBD
- Validate the use of inflammatory markers to define disease activity and optimize the management of IBD
- Consider combination therapy and explore the best use of immunomodulators to optimize combination therapy in IBD
- Examine anti-TNF drug and antibody levels to optimize dosing
- Discuss the treatment and follow-up of Clostridium difficile infection in IBD
- Review the CAG Position Statement on fecal microbiota transplantation and assess independent reports from 2 Canadian randomized-controlled FMT trials
- Survey current IBD literature
Optimizing Management in IBD: What we (think) we know?
Presented by Brian G. Feagan, MD
State-of-the-art Plenary Presentation
Optimizing Management Using CRP, Fecal Calprotectin and Ferritin
Presented by Peter L. Lakatos, MD
State-of-the-art Plenary Presentation
Optimizing Management Using Combination Therapy
Presented by Simon PL. Travis, DPhil FRCP
State-of-the-art Plenary Presentation
Optimizing Management with Anti-TNF Levels and Antibodies
Presented by Shomron Ben-Horin, MD
State-of-the-art Plenary Presentation
Optimizing Management Using the Treat-to-Target Approach
Presented by Subrata Ghosh, MD
State-of-the-art Plenary Presentation
Management of Clostridium difficile Infection in Patients with IBD
Presented by Lawrence J. Brandt, MD
State-of-the-art Plenary Presentation
The CAG Position Statement and a Report from McMaster's Fecal Microbiota Transplantation Randomized-controlled Trial
Presented by John K. Marshall, MD
State-of-the-art Plenary Presentation